Innocell completes Phase 3 trial on Immuncell-LC

Published: 2012-12-03 06:56:00

Updated: 2012-12-03 06:56:00

Innocell, a local biopharmaceutical company, said Thursday that it has completed its Phase 3 clinical trial on Immuncell-LC, which is an activated T-lympho therapy drug that uses the patient's own lymphocytes for the removal of residual cancer cells and prevention of its recurrence after the remo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK